Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus

被引:28
|
作者
Kuranov, S. O. [1 ]
Tsypysheva, I. P. [2 ]
Khvostov, M., V [1 ,5 ]
Zainullina, Liana F. [3 ,4 ]
Borisevich, S. S. [2 ]
Vakhitova, Yu V. [3 ,4 ]
Luzina, O. A. [1 ]
Salakhutdinov, N. F. [1 ,5 ]
机构
[1] Russian Acad Sci, Siberian Branch, NN Vorozhtsov Novosibirsk Inst Organ Chem, Novosibirsk 630090, Russia
[2] Russian Acad Sci, Ufa Inst Chem, Ufa 450054, Russia
[3] FSBI Zalcusov Inst Pharmacol, Moscow 125315, Russia
[4] IBG UFRC RAS, Ufa 450054, Russia
[5] Novosibirsk State Univ, Novosibirsk 630090, Russia
关键词
DIPEPTIDYL-PEPTIDASE-IV; COMPLICATIONS; EPIDEMIOLOGY; DERIVATIVES; INSULIN; DESIGN; POTENT; DRUGS;
D O I
10.1016/j.bmc.2018.07.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, bornyl- and cytisine-based cyanopyrrolidines as potent dipeptidyl peptidase-IV (DPP-IV) inhibitors were synthesised. The in vitro inhibiting activities of bornyl- and cytisine derivatives towards DPP-IV were evaluated. Bornyl-based cyanopyrrolidines were shown to have moderate inhibitory activity with regard to DPP-IV (1.27-15.78 mu M). A docking study was performed to elucidate the structure-activity relationship of the obtained compounds. The in vivo hypoglycemic activities of the same compounds were evaluated with the oral glucose tolerance test (OGTT) in mice. Bornyl-based cyanopyrrolidines were shown to have good hypoglycemic activity.
引用
收藏
页码:4402 / 4409
页数:8
相关论文
共 50 条
  • [41] MEDI 415-Cyclopropylglycine amide derivatives as potent DPP-IV inhibitors for the treatment of diabetes
    Thomas, Abraham
    Kadam, Ashok
    Pawar, Mangesh
    Shah, Daisy
    Varanasi, Kanthikiran
    Raghuram, Anupindi
    Narayanan, Shridhar
    Vakkalanka, Swaroop V.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [42] Efficacy and Safety of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects with Type 2 Diabetes Mellitus
    Terra, Steven G.
    Somayaji, Veena
    Teeter, John G.
    Dai, Haiqing
    Nguyen, Tu T.
    Ghazzi, Mahmoud
    DIABETES, 2009, 58 : A134 - A135
  • [43] To investigate the efficacy of dipeptidyl peptidase-IV (DPP-IV) inhibitor therapy in multiethnic Asian patients with type 2 diabetes mellitus
    Andres, Julia
    Yeo, Jia Xuan
    Khoo, Chin Meng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S123 - S124
  • [44] Comparison of the Efficacy and β-Cell Function In DPP-IV Inhibitors Treated Type 2 Diabetes Patients between Asian and Caucasian
    Cai, Xiaoling
    Han, Xueyao
    Luo, Yingying
    Ji, Linong
    DIABETES, 2013, 62 : A667 - A667
  • [45] Virtual Screening, Synthesis, and Biological Evaluation of Some Carbohydrazide Derivatives as Potential DPP-IV Inhibitors
    Jadhav, Prerana B. B.
    Jadhav, Shailaja B. B.
    Zehravi, Mehrukh
    Mubarak, Mohammad S. S.
    Islam, Fahadul
    Jeandet, Philippe
    Khan, Sharuk L. L.
    Hossain, Nazmul
    Rashid, Salma
    Ming, Long Chiau
    Sarker, Md. Moklesur Rahman
    Azlina, Mohd Fahami Nur
    MOLECULES, 2023, 28 (01):
  • [46] Assessment of Changes in Dipeptidyl-peptidase-IV (DPP-IV) Enzyme Activity in Type 1 and Type 2 Diabetes
    Stevenson, C. L.
    Abdel-Wahab, Y. H. A.
    O'Kane, M. J.
    McKillop, A. M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S344 - S344
  • [47] The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies
    Chen, Zhongqin
    Su, Xiaojie
    Cao, Wenhong
    Tan, Mingtang
    Zhu, Guoping
    Gao, Jialong
    Zhou, Longjian
    MARINE DRUGS, 2024, 22 (08)
  • [48] Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and in vitro biological evaluation
    Abu Khalaf, Reema
    Alwarafi, Ebtisam
    Sabbah, Dima
    ACTA PHARMACEUTICA, 2021, 71 (04) : 631 - 643
  • [49] Synthesis of 3,3-Dimethylglutamic Acid Derivatives as DPP-IV Inhibitors and Evaluation of Their Chemical Stability
    Hsu, Tsu
    Tsai, Ting-Yueh
    Tseng, Ya-Ju
    Chiou, Mei-Chun
    Lu, Cheng-Tai
    Chao, Yu-Sheng
    Jiaang, Weir-Torn
    JOURNAL OF THE CHINESE CHEMICAL SOCIETY, 2011, 58 (01) : 108 - 117
  • [50] Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: For GLP-1/DPP-IV inhibitors
    Kumar, Ajay
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 21 - 25